TA1

Thymosin alpha-1 is a 28-amino-acid synthetic peptide identical to the endogenous thymic peptide, studied in immune-modulation research models. Lyophilized powder. Reconstitute with bacteriostatic water for in-vitro research. Store at -20°C. Certificate of Analysis attached to this listing.

Potential T-cell and immune signaling modulation.

Thymosin Alpha-1 (TA1) is a 28-amino-acid peptide that is naturally produced by the thymus gland. Its primary role is to train and coordinate immune cells that are essential for combating viruses and other infections. The synthetic version of TA1, known as thymalfasin, is marketed under the brand name Zadaxin and has received approval in over 35 countries for the treatment of chronic hepatitis B, chronic hepatitis C, and as an adjunct in cancer care. However, it is important to note that TA1 is not FDA-approved in the United States and is currently under review for inclusion on the 503A bulk drug substances list.

The mechanism of action of TA1 involves enhancing cell-mediated immunity, which is crucial for the body’s defense against pathogens. It achieves this by stimulating the proliferation and activity of T-cells, which are vital components of the immune system. This immune activation is particularly beneficial in patients with chronic viral infections and those undergoing cancer treatments, where immune support is critical. The standard clinical dosing schedule for TA1, validated in chronic hepatitis B trials, is 1.6 mg administered subcutaneously twice weekly for a duration of 6 to 12 months.

Clinical evidence supporting the efficacy of TA1 varies by indication. For chronic hepatitis B, pooled analyses of randomized controlled trials (RCTs) have demonstrated significant advantages in sustained virologic response compared to placebo. In chronic hepatitis C, TA1 has shown moderate efficacy when used in conjunction with interferon, although newer direct-acting antiviral therapies have diminished its relevance. In cancer care, smaller studies suggest that TA1 may reduce infection rates and preserve immune function during chemotherapy, although the evidence is less robust and fragmented. The use of TA1 in severe sepsis has yielded mixed results, with a large trial showing no significant mortality benefit, while a meta-analysis suggested potential benefits but flagged concerns regarding the reliability of the data.

Overall, TA1 acts as an immune modulator, enhancing the body’s immune response, which can be particularly advantageous in specific clinical contexts, such as chronic viral infections and cancer treatment. [Source: Peptide Dosing Protocols]

Amino sequence: Ac-SDAAVDTSSEITTKDLKEKKEVVEEAEN

COA: View certificate (batch TET-4701-A) →

Teton Labs product catalog · research-use compound data.